Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in ...

Time costs, often overlooked in health care, create economic burdens for patients and caregivers, impacting income and ...

Ten children who received DB-OTO for profound genetic hearing loss due to variants of the otoferlin gene showed notable ...

With the potential for future pandemics, Chun Chao, PhD, MS, emphasizes the importance of learning from the COVID-19 pandemic's impact on cancer care, particularly for patients with ovarian cancer.

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Lidia Schapira, MD, FASCO, professor of medicine at Stanford Medicine, medical oncologist, and director for the Stanford Cancer Institute and the Stanford Comprehensive Cancer Center, discusses the ...

Andrew S. Oseran, MD, MBA, MSc, hypothesizes that higher Medicare Advantage (MA) risk scores may result from either a more accurate capture of beneficiaries' comorbidities or inappropriate "upcoding" ...

The Braidwood Management v Becerra decision could require payers to step up to continue covering preventive services, ...

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

Panelists discuss how the successful management of iron deficiency anemia requires a comprehensive approach combining early detection, appropriate choice of iron formulation, careful monitoring of ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...